Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- Japan Vaccine Market Projected to Top 280 Billion Yen in FY2024: Fuji Keizai
June 6, 2024
- PharmaEssentia’s Besremi Gets Health Coverage for Self-Injection
June 5, 2024
- China Outpaces US in Oncology Trials, Japan’s Share Sags: IQVIA
June 5, 2024
- Twymeeg Tops April GP Rep Promotion Rankings: Intage
June 5, 2024
- Lilly’s Ulcerative Colitis Therapy Omvoh Now Available for Self-Injection
June 4, 2024
- Regeneron Takes Over Japan Marketing Authorization for Libtayo from Sanofi
June 4, 2024
- Organon Launches Fertility Med Follistim after Re-Submission
June 4, 2024
- EU Panel OKs Adzynma for cTTP under Exceptional Circumstances
June 4, 2024
- Janssen Files Amivantamab for Post-Tagrisso NSCLC Setting in Japan
June 3, 2024
- Bayer, Kyoto University Form Strategic Alliance to Fuel Innovation
June 3, 2024
- Tapinarof Cream Hits Main Goal in PIII Eczema Trial in Children: JT/Torii
June 3, 2024
- ASKA Extends Relugolix Combo Deal with Takeda into Endometriosis
June 3, 2024
- FDA Accepts Re-Filing of Astellas’ Gastric Cancer Med for Review
June 3, 2024
- Lilly Rolls Out Eczema Drug Ebglyss in Japan
June 3, 2024
- Pfizer’s RSV Vaccine Abrysvo Now Available in Japan
June 3, 2024
- Moderna Submits RSV Vaccine in Japan
May 31, 2024
- Nxera Gets US$4.6 Million Milestone over Centessa’s OX2R Agonist
May 31, 2024
- Viatris Launches Cystadrops, Its 1st Brand-Name Product in Japan
May 31, 2024
- Takeda’s cTTP Drug Adzynma Now Available in Japan
May 31, 2024
- Kaken to Transfer Bispecific IP to J&J as US Giant Nabs Asset
May 30, 2024
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…